Patricia S. Andrews
The CanStem111P trial, which was evaluating the combination of napabucasin, weekly nab-paclitaxel (Abraxane), and gemcitabine compared with nab-paclitaxel/gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma, will be discontinued due to futility, according to Boston Biomedical, the manufacturer of the investigational agent.1
Napabucasin is also being investigated in the ongoing phase III CanStem303C trial (NCT02753127) in patients with metastatic colorectal cancer, as well as in earlier-phase trials in multiple solid malignancies.
- Boston Biomedical, Inc. Announces Update on Phase 3 Canstem111p Study of Napabucasin in Patients With Metastatic Pancreatic Cancer Following Interim Analysis. Boston Biomedical. Published July 1, 2019. https://bit.ly/2Nv0m3F. Accessed July 1, 2019.
- Starodub A, El-Rayes B, O’Neil B, et al. A phase Ib/II study of cancer stemness inhibitor napabucasin in combination with gemcitabine (gem) & nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts). Ann Oncol. 2017;28(suppl 3);iii150-iii153. doi: 10.1093/annonc/mdx302.
... to read the full story